Chloral hydrate - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Identification

Name

Chloral hydrate

Accession Number

DB01563

Type

Small Molecule

Groups

Approved, Illicit, Vet Approved

Description

A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1,1,1-trichloro-2,2-dihydroxyethane

1,1,1-trichloro-2,2-ethanediol

2,2,2-trichloro-1,1-ethanediol

chloral monohydrate

Chloralhydrat

Trichloracetaldehyd-hydrat

trichloroacetaldehyde hydrate

External IDs

NSC-3210

Product Ingredients

Not Available

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Chloral Hydrate Capsules 500mg	Capsule	500 mg	Oral	D.C. Labs Limited	1968-12-31	2003-07-11	Canada
Chloral Hydrate Syrup Odan	Syrup	100 mg	Oral	Odan Laboratories Ltd	2003-08-06	Not applicable	Canada
Novo-chlorhydrate Cap 500mg	Capsule	500 mg	Oral	Novopharm Limited	1967-12-31	2005-08-10	Canada
PMS-chloral Hydrate Capsules 500mg	Capsule	500 mg	Oral	Pharmascience Inc	1996-10-10	Not applicable	Canada
PMS-chloral Hydrate Syrup 100mg/ml	Syrup	100 mg	Oral	Pharmascience Inc	1990-12-31	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-chloral Hydrate Syrup	Syrup	100 mg	Oral	Apotex Corporation	Not applicable	Not applicable	Canada

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Aquachloral Supprettes	Amerifit Pharma
Somnote	Breckenridge

Brand mixtures

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Analgesic Balm	Chloral hydrate Menthol Methyl salicylate	Ointment	Topical	D.C. Labs Limited	1966-12-31	2003-07-11	Canada
Calmitol Itching Relief Ont	Camphor Chloral hydrate Hyoscyamine Menthol Zinc oxide	Ointment	Topical	Pfizer Canada Inc., Consumer Healthcare Division	1964-12-31	1996-09-09	Canada

Categories

UNII

418M5916WG

CAS number

302-17-0

Weight

Average: 165.403
Monoisotopic: 163.919862461

Chemical Formula

C₂H₃Cl₃O₂

InChI Key

RNFNDJAIBTYOQL-UHFFFAOYSA-N

InChI

InChI=1S/C2H3Cl3O2/c3-2(4,5)1(6)7/h1,6-7H

IUPAC Name

2,2,2-trichloroethane-1,1-diol

SMILES

OC(O)C(Cl)(Cl)Cl

Pharmacology

Indication

Mainly used as a hyponotic in the treatment of insomnia; however, it is only effective as a hypnotic for short-term use. May be used as a routine sedative preoperatively to decrease anxiety and cause sedation and/or sleep with respiration depression or cough reflex.

Structured Indications

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Rapidly absorbed in the GI tract following oral or rectal administration. Chloral hydrate and its active metabolite, trichloroethanol, have been detected in CSF, umbilical cord blood, fetal blood, and amniotic fluid.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Metabolized by the liver and erythrocytes to form trichloroethanol, an active metabolite. This reaction is catalyzed by alcohol dehydrogenase and other enzymes. Oxidation of chloral hydrate and trichloroethanol to trichloroacetic acid in the liver and kidneys also occurs to a lesser extent. Trichloroethanol also undergoes glucuronidation to produce an inactive metabolism.

Route of elimination

Trichloroethanol, trichloroethanol glucuronide, and trichloroacetic acid are excreted in the urine. Some trichloroethanol glucuronide may be secreted into bile and excreted in the feces.

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with 7-Nitroindazole.	Experimental
Acenocoumarol	The serum concentration of Acenocoumarol can be increased when it is combined with Chloral hydrate.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Aceprometazine.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Agomelatine.	Approved, Investigational
Alfaxalone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Chloral hydrate.	Approved, Illicit
Allopregnanolone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sage 547.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chloral hydrate.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Chloral hydrate.	Approved, Illicit, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amitriptyline.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Chloral hydrate.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amperozide.	Experimental
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloral hydrate.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Asenapine.	Approved
Azelastine	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Azelastine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Barbital is combined with Chloral hydrate.	Illicit
Benperidol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Benperidol.	Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Benzocaine is combined with Chloral hydrate.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Benzyl alcohol.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Chloral hydrate.	Approved, Illicit
Brompheniramine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brotizolam.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloral hydrate.	Approved, Investigational
Buprenorphine	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Chloral hydrate.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Chloral hydrate.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Butalbital.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Chloral hydrate.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloral hydrate.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Chloral hydrate.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Carisoprodol.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cetirizine.	Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chloral hydrate.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Chloral hydrate.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chloral hydrate.	Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Chlorphenamine.	Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloral hydrate.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chloral hydrate.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Chlorzoxazone.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloral hydrate.	Approved, Vet Approved
Citalopram	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Citalopram.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clobazam.	Approved, Illicit
Clomipramine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clonidine.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Chloral hydrate.	Approved, Illicit
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Chloral hydrate.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Chloral hydrate.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Chloral hydrate.	Approved, Illicit
Cyclizine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloral hydrate.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cyproheptadine.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dantrolene.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloral hydrate.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dapoxetine.	Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Chloral hydrate.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desvenlafaxine.	Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloral hydrate.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Chloral hydrate.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloral hydrate.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Chloral hydrate.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Dicoumarol	The serum concentration of Dicoumarol can be increased when it is combined with Chloral hydrate.	Approved
Difenoxin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chloral hydrate.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chloral hydrate.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dihydromorphine.	Experimental, Illicit
Dimenhydrinate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloral hydrate.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloral hydrate.	Approved, Illicit
Doxepin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Doxepin.	Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Chloral hydrate.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Chloral hydrate.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Efavirenz.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pregnanolone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Chloral hydrate.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Entacapone.	Approved, Investigational
Escitalopram	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Escitalopram.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Chloral hydrate.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloral hydrate.	Approved
Ethanol	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloral hydrate.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethotoin.	Approved
Ethyl biscoumacetate	The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Chloral hydrate.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chloral hydrate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chloral hydrate.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Chloral hydrate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Chloral hydrate.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Chloral hydrate.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fexofenadine.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Flibanserin.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fludiazepam.	Approved, Illicit
Fluindione	The serum concentration of Fluindione can be increased when it is combined with Chloral hydrate.	Investigational
Flunarizine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chloral hydrate.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Flupentixol is combined with Chloral hydrate.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloral hydrate.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Chloral hydrate.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluspirilene.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chloral hydrate.	Approved, Investigational
Fosphenytoin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fospropofol.	Approved, Illicit
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Chloral hydrate.	Approved, Vet Approved
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Chloral hydrate.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with gabapentin enacarbil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chloral hydrate.	Approved, Illicit
Gepirone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Chloral hydrate.	Approved, Illicit
Guanfacine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Chloral hydrate.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Chloral hydrate.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Chloral hydrate.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Chloral hydrate.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Hexobarbital is combined with Chloral hydrate.	Approved
Hydrocodone	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloral hydrate.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Iloperidone.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Indalpine.	Investigational, Withdrawn
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Chloral hydrate.	Approved, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Chloral hydrate.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketobemidone.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lamotrigine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chloral hydrate.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chloral hydrate.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Chloral hydrate.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Chloral hydrate.	Approved, Vet Approved
Lithium	The risk or severity of adverse effects can be increased when Lithium is combined with Chloral hydrate.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lofentanil.	Illicit
Loratadine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Chloral hydrate.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Chloral hydrate.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lurasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved, Vet Approved
Maprotiline	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Maprotiline.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Meclizine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Chloral hydrate.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Melperone.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloral hydrate.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chloral hydrate.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloral hydrate.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Chloral hydrate.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chloral hydrate.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Chloral hydrate.	Approved
Methotrimeprazine	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloral hydrate.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with ECGONINE METHYL ESTER.	Experimental
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloral hydrate.	Approved
Metyrosine	Chloral hydrate may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Chloral hydrate.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Milnacipran.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved, Investigational
Mirtazapine	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Molindone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Molindone.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Chloral hydrate.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved, Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloral hydrate.	Approved
Nefazodone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nefazodone.	Approved, Withdrawn
Nitrazepam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nitrazepam.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nitrous oxide.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nortriptyline.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Ondansetron is combined with Chloral hydrate.	Approved
Opium	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Opium.	Approved, Illicit
Orphenadrine	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Osanetant.	Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Chloral hydrate.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chloral hydrate.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Chloral hydrate.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Chloral hydrate.	Approved, Investigational, Vet Approved
Paliperidone	The risk or severity of adverse effects can be increased when Paliperidone is combined with Chloral hydrate.	Approved
Paraldehyde	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Paroxetine.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chloral hydrate.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloral hydrate.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved
Perazine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perazine.	Investigational
Perospirone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Chloral hydrate.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Chloral hydrate.	Approved
Phenindione	The serum concentration of Phenindione can be increased when it is combined with Chloral hydrate.	Approved
Phenobarbital	The risk or severity of adverse effects can be increased when Phenobarbital is combined with Chloral hydrate.	Approved
Phenprocoumon	The serum concentration of Phenprocoumon can be increased when it is combined with Chloral hydrate.	Approved
Phenytoin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pimozide is combined with Chloral hydrate.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Piritramide.	Investigational
Pomalidomide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pomalidomide.	Approved
Pramipexole	Chloral hydrate may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Prazepam.	Approved, Illicit
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Chloral hydrate.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Chloral hydrate.	Approved
Primidone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Chloral hydrate.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloral hydrate.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Chloral hydrate.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Promethazine.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Chloral hydrate.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Chloral hydrate.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Propoxycaine.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Protriptyline.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Quazepam.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Chloral hydrate.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ramelteon.	Approved, Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Chloral hydrate.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Chloral hydrate.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Chloral hydrate.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Risperidone is combined with Chloral hydrate.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ritanserin.	Investigational
Ropinirole	Chloral hydrate may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloral hydrate.	Approved
Rotigotine	Chloral hydrate may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Chloral hydrate.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Chloral hydrate.	Approved, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sertindole.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Chloral hydrate.	Approved, Vet Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Chloral hydrate.	Approved
Suvorexant	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tasimelteon.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Chloral hydrate.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrodotoxin.	Investigational
Thalidomide	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Chloral hydrate.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Chloral hydrate.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Chloral hydrate.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiapride.	Approved, Investigational
Tizanidine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tizanidine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tolcapone.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Topiramate.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Chloral hydrate.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloral hydrate.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Chloral hydrate.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Chloral hydrate.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloral hydrate.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloral hydrate.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Triprolidine.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Chloral hydrate.	Approved, Investigational
Venlafaxine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Venlafaxine.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vigabatrin.	Approved
Vortioxetine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vortioxetine.	Approved
Warfarin	The serum concentration of Warfarin can be increased when it is combined with Chloral hydrate.	Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Chloral hydrate.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloral hydrate.	Approved
Zolpidem	Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Chloral hydrate.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB60451
KEGG Drug	D00265
KEGG Compound	C06899
PubChem Compound	2707
PubChem Substance	46507155
ChemSpider	2606
ChEBI	28142
ChEMBL	CHEMBL455917
PharmGKB	PA448925
Drug Product Database	10068
RxList	http://www.rxlist.com/cgi/generic/chloralhyd.htm
Drugs.com	http://www.drugs.com/cdi/chloral-hydrate.html
Wikipedia	Chloral_hydrate

ATC Codes

N05CC01 — Chloral hydrate

AHFS Codes

28:24.92

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Not Available	Auditory Brainstem Response in Children / Sedation With Chloral Hydrate	1
2	Withdrawn	Diagnostic	Computerized tomography / Procedural Sedation / Traumatic Brain Injury (TBI)	1
2	Withdrawn	Treatment	Procedural Sedation	1
3	Active Not Recruiting	Diagnostic	Children / Electroencephalogram / Epilepsies / Sedation therapy	1
3	Completed	Treatment	Other Conditions of Brain	1
3	Recruiting	Treatment	Anxiety Disorder / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders	1
4	Completed	Treatment	Heart Diseases	1
4	Completed	Treatment	Sedation therapy	1
Not Available	Completed	Not Available	Pediatric	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Dosage forms

Form	Route	Strength
Ointment	Topical
Capsule	Oral	500 mg
Syrup	Oral	100 mg

Prices

Unit description	Cost	Unit
Pms-Chloral Hydrate 100 mg/ml Syrup	0.05USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	57 °C	PhysProp
boiling point (°C)	98 °C	PhysProp
water solubility	7.93E+005 mg/L (at 25 °C)	YALKOWSKY,SH & HE,Y (2003)
logP	0.99	HANSCH,C ET AL. (1995)

Predicted Properties

Property	Value	Source
Water Solubility	43.4 mg/mL	ALOGPS
logP	0.88	ALOGPS
logP	0.69	ChemAxon
logS	-0.58	ALOGPS
pKa (Strongest Acidic)	9.51	ChemAxon
pKa (Strongest Basic)	-5.1	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	40.46 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	29.25 m³·mol^-1	ChemAxon
Polarizability	11.88 Å³	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9591
Blood Brain Barrier	+	0.9555
Caco-2 permeable	-	0.5795
P-glycoprotein substrate	Non-substrate	0.8757
P-glycoprotein inhibitor I	Non-inhibitor	0.9923
P-glycoprotein inhibitor II	Non-inhibitor	0.9794
Renal organic cation transporter	Non-inhibitor	0.9454
CYP450 2C9 substrate	Non-substrate	0.7898
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Non-substrate	0.7558
CYP450 1A2 substrate	Non-inhibitor	0.7969
CYP450 2C9 inhibitor	Non-inhibitor	0.8017
CYP450 2D6 inhibitor	Non-inhibitor	0.9417
CYP450 2C19 inhibitor	Non-inhibitor	0.847
CYP450 3A4 inhibitor	Non-inhibitor	0.9446
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9778
Ames test	AMES toxic	0.6454
Carcinogenicity	Carcinogens	0.616
Biodegradation	Not ready biodegradable	0.8453
Rat acute toxicity	2.5068 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9837
hERG inhibition (predictor II)	Non-inhibitor	0.9558

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (8.88 KB)

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as chlorohydrins. These are alcohols substituted by a chlorine atom at a saturated carbon atom otherwise bearing only hydrogen or hydrocarbyl groups.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organohalogen compounds

Sub Class

Halohydrins

Direct Parent

Chlorohydrins

Alternative Parents

Carbonyl hydrates / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides

Substituents

Chlorohydrin / Carbonyl hydrate / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Organochloride / Alkyl halide / Alkyl chloride / Aliphatic acyclic compound

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

organochlorine compound, aldehyde hydrate, ethanediol (CHEBI:28142 ) / a small molecule (CPD0-1476 )

Drug created on July 31, 2007 07:10 / Updated on August 02, 2017 16:34

Structure for DB01563 (Chloral hydrate)